Simpler trials would encourage more heart drugs

18th June 2015

Leading European heart experts are calling for simpler drug trials to encourage pharmaceutical companies to develop more heart drugs.

The European Society of Cardiology (ESC) says that the large and lengthy studies needed to prove drugs are safe and effective are a disincentive to drug developers.

It said the large group of patients and the long time needed to prove a heart drug works make for costly and inefficient trials.

Author Paulus Kirchhof said: “Cardiovascular drug development is partially a victim of its own success."

For details.